Emerging Therapies and the Evolving Role of Pharmacists in Myelofibrosis Management

Research in myelofibrosis continues to expand beyond JAK inhibitors, with several novel therapies under investigation. These include agents targeting fibrotic pathways, apoptosis regulators, and epigenetic modifiers, many of which are being studied in combination with JAK inhibitors to enhance efficacy, address anemia, and potentially modify disease progression. The evolving therapeutic landscape will require nuanced treatment sequencing and individualized approaches based on patient characteristics and molecular profiles. Pharmacists are expected to play an increasingly pivotal role over the next five years, not only in monitoring adverse events and optimizing dosing, but also in guiding combination therapies, supporting adherence, and facilitating access to emerging treatments. Panelists emphasized the importance of multidisciplinary collaboration, early intervention, and personalized care to maximize patient outcomes, underscoring the need for continuous integration of clinical, pharmacologic, and patient-centered expertise in myelofibrosis management.